<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540501</url>
  </required_header>
  <id_info>
    <org_study_id>NAI108166</org_study_id>
    <nct_id>NCT00540501</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects</brief_title>
  <official_title>Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is a 4 period study to see if there is any interaction between Orally-Administered
      Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Contract agreement not reached
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2007</completion_date>
  <primary_completion_date type="Anticipated">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oseltamivir carboxylate levels: Cmax and AUC(0-12)-</measure>
    <time_frame>Period 2: Day 1, 2 &amp; 3. Period 3: Day 1, 2 &amp; 3. Period 4: Day 1, 2 &amp; 3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oseltamivir: Cmax, AUC(0-12)&amp; C12. Oseltamivir carboxylate: C12, AUC(0-24)&amp; t1/2.</measure>
    <time_frame>Period 2-4 Day 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zanamivir: Cmax, AUC(0-12), C12, t1/2, CL, tmax &amp; V2 .</measure>
    <time_frame>Period 1, 3 &amp; 4 Day 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety:labs, vitals, ECGs &amp; AEs.</measure>
    <time_frame>Period 1-4, Days 1-4.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Oseltamivir 150mg and zanamivir 50mg/hour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zanamivir IV 50mg/hour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir 150mg and zanamivir 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir 150mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir 150mg PO q12h for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir and Intravenous Zanamivir</intervention_name>
    <description>Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.
Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.
Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes.</description>
    <arm_group_label>Oseltamivir 150mg</arm_group_label>
    <arm_group_label>Oseltamivir 150mg and zanamivir 50mg/hour</arm_group_label>
    <arm_group_label>Oseltamivir 150mg and zanamivir 600mg</arm_group_label>
    <arm_group_label>Zanamivir IV 50mg/hour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy Volunteer(s)confirmed by physical exam, clinical labs, ECGs, and vitals

          -  Must be woman of non-childbearing potential or willing to abstain from intercourse for
             two weeks prior to study drug administration and throughout the study or be willing to
             use two acceptable methods of birth control.

        Exclusion criteria:

          -  Subjects with history of certain heart problems or subjects with Hepatitis B, C or
             HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>zanamivir,</keyword>
  <keyword>influenza virus,</keyword>
  <keyword>healthy volunteer,</keyword>
  <keyword>PK, drug interaction,</keyword>
  <keyword>IV, and oseltamivir.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Zanamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

